Фидасимтамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2377419-89-9

immunoglobulin G1-kappa, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)] and anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens and humanized monoclonal antibody, bispecific;
gamma1 heavy chain Homo sapiens anti-PDCD1 (1-450) [VH anti-PDCD1 (Homo sapiens IGHV1-69*01 (95.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361), T22>L (369), D84.2>R (402) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain Homo sapiens anti-PDCD1 (1'-214') [V-KAPPA anti-PDCD1 (Homo sapiens IGKV1-12*01 (96.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain humanized anti-ERBB2 (1''-450'') [VH anti-ERBB2 (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1''-120'') -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (217) (121''-218''), hinge 1-15 (219''-233''), CH2 (234''-343''), CH3 L7>E (354), D12 (359), L14 (361), Y86>L (410), K88>V (412) (344''-448''), CHS (449''-450'')) (121''-450'')], (223''-214''')-disulfide with kappa light chain humanized anti-ERBB2 (1'''-214''') [V-KAPPA anti-ERBB2 (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line lacking the glutamine synthetase gene (GSKO), glycoform alfa

Поделиться этой страницей